Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure.
The two most serious symptoms of fulminant hepatic failure are bleeding and hepatic coma. To overcome these problems, we developed an artificial liver support system comprising a combination of plasma exchange and hemodiafiltration using a high performance membrane. We treated 67 patients with fulminant hepatic failure. Of these, 65 patients (97.0%) regained normal consciousness, and 55 patients (80.9%) were kept alert as long as we continued to apply this system. All 7 patients (100%) with fulminant hepatitis caused by hepatitis A virus infection and 9 of 12 patients (75%) with fulminant hepatitis caused by acute hepatitis B (HB) virus infection survived. In addition, 7 of 15 HB virus carriers (46.7%) who developed fulminant hepatitis and 11 of 29 patients (37.9%) with fulminant hepatitis caused by non-A, non-B hepatitis viruses survived. The overall survival rate was 37 of 67 patients (55.2%). Our artificial liver support system allows as high a survival rate as liver transplantation.
Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama City, Japan.
M
M
Yoshiba
K
K
Inoue
K
K
Sekiyama
I
I
Koh
D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D017583:Hemodiafiltration / Q000592:standards*; D006470:Hemorrhage / Q000517:prevention & control; D006501:Hepatic Encephalopathy / Q000401:mortality / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy*; D006506:Hepatitis A / Q000401:mortality / Q000503:physiopathology; D006509:Hepatitis B / Q000401:mortality / Q000503:physiopathology; D006526:Hepatitis C / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D019164:Liver, Artificial; D008137:Longitudinal Studies; D008297:Male; D008567:Membranes, Artificial; D016896:Treatment Outcome
D008567:Membranes, Artificial